Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Molecular prognostication in bladder cancer--a current perspective.

M L Quek1, D I Quinn, S Daneshmand

  • 1Department of Urology, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles 90089, USA. quekm@hsc.usc.edu

European Journal of Cancer (Oxford, England : 1990)
|July 12, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A simple plan: chemotherapy-sparing approaches to early-stage and regional seminoma and nonseminoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Favorable long-term Health Related Quality of Life in cured survivors of testicular cancer management. So, what now?

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Penile Paget's Disease: A Case Report and Review of the Literature.

Archives of nephrology and urology·2023
Same author

Corrigendum to "Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium" [Eur Urol Focus 2021;7:1347-54].

European urology focus·2022
Same author

ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups.

ESMO open·2021

Accurate bladder cancer management relies on assessing tumor potential. Research into molecular markers for transitional cell carcinoma (TCC) aims to improve patient outcomes and treatment response.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Optimal bladder cancer management requires accurate assessment of tumor biological potential.
  • Transitional cell carcinoma (TCC) is the most common type of bladder cancer.
  • Molecular and cytogenetic advancements are crucial for identifying prognostic markers.

Purpose of the Study:

  • To review the molecular changes associated with bladder cancer.
  • To highlight the role of prognostic markers in patient management.
  • To discuss the translation of novel markers from research to clinical practice.

Main Methods:

  • Review of current literature on molecular biology and cytogenetics in bladder cancer.
  • Categorization of molecular alterations into carcinogenesis, cell cycle control, and metastasis.

Related Experiment Videos

  • Discussion of the clinical implications of these molecular changes.

    • Main Results:

    • Molecular changes include chromosomal alterations, dysregulated cell cycle control, and angiogenesis.
    • These accumulated changes determine tumor behavior and therapy response.
    • Novel molecular markers hold promise for improved prognostication.

    Conclusions:

    • Understanding molecular changes in bladder cancer is key to personalized management.
    • Prognostic markers derived from molecular research can enhance clinical decision-making.
    • Future research will likely yield new molecular tools for better bladder cancer outcomes.